FGF19 and FGF21 serum concentrations in human obesity and type 2 diabetes behave differently after diet- or surgically-induced weight loss.
Sign Up to like & getrecommendations! Published in 2017 at "Clinical nutrition"
DOI: 10.1016/j.clnu.2016.04.027
Abstract: BACKGROUND & AIMS Fibroblast growth factor 19 (FGF19) and 21 (FGF21) have emerged as key regulators of energy homeostasis. Our aim was to analyze the impact of weight loss (WL) induced either by conventional dietary… read more here.
Keywords: serum concentrations; weight loss; fgf19 fgf21; fgf21 ... See more keywords
FGF19 and FGF21: In NASH we trust
Sign Up to like & getrecommendations! Published in 2020 at "Molecular Metabolism"
DOI: 10.1016/j.molmet.2020.101152
Abstract: Objective FGF19 and FGF21 have shown therapeutic promise since their discovery, attested by the fact there are at least 5 assets that activate the FGFR/KLB pathway and one FGF19 analog in clinical development. Methods We… read more here.
Keywords: nash trust; fgf21 nash; fgf19 fgf21; fgf19 ... See more keywords
Obesity: Pharmacological actions of FGF19 and FGF21 revealed
Sign Up to like & getrecommendations! Published in 2017 at "Nature Reviews Endocrinology"
DOI: 10.1038/nrendo.2017.144
Abstract: The mechanisms that underlie the pharmacological effects of fibroblast growth factor 19 (FGF19), FGF21 and FGF mimetic antibodies are not well understood. Now, David Mangelsdorf, Steven Kliewer and colleagues report that FGF21, FGF19 and bFKB1,… read more here.
Keywords: nervous system; obesity pharmacological; pharmacological effects; fgf19 fgf21 ... See more keywords